Cost ReductionGH successfully cut Reveal's unit COGS by 50% recently due to a change in workflows, which should swing Reveal into GM-positive territory.
Medicare CoverageMedicare coverage for Reveal in the surveillance setting could position GH to address a significantly larger portion of the overall minimal residual disease (MRD) market opportunity.
Revenue GrowthStrong preliminary 4Q24 results were well ahead of expectations, driven by solid growth in clinical and biopharma test volumes.